TS-062690 — Novel niclosamide analogues with improved bioavailability and mitigated dose-limiting toxicities.

TS-062685 — Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths. The most common cancers are breast, lung, colon and rectum and prostate cancers. The Need Current cancer treatments mainly rely on chemotherapy, radiation, surgery and bon…

TS-062680 — According to the American Cancer Society, breast cancer is the most common cancer for women in the US, except for skin cancer. It comprised about 30% of all new female cancers each year. While breast cancer death rates have decreased over the last several decades, it remains the second leading cause…

TS-062605 — The Need: Castration-resistant prostate cancer (CRPC) poses a significant challenge in oncology, with existing therapies often leading to resistance and disease progression. Key drivers of resistance include the androgen receptor (AR) and aldo-keto reductase family 1 member C3 (AKR1C3). Novel treat…

TS-050220 — Novel natural products and derivatives thereof that exhibit potent in vitro and in vivo activity

TS-047118 — Analogues of verticillin with significantly improved drug-like properties, including increased solubility, absorption, and stability, while maintaining similar anticancer potency as the verticillin parent compounds.

TS-044109 — Lipid nanoparticles (LNs) usable for the delivery of therapeutic compositions, including, but not limited to nucleic acids (NAs).

TS-037724 — Researchers at The Ohio State University have discovered Compound 13, a patent protected, orally bioavailable and brain penetrant Mps1/TTK inhibitor that exhibits single agent tumor growth inhibition in a murine xenograft model of human triple negative breast cancer upon daily administration.

TS-037721 — A group of potential antitumor arylnapthalene lactone derivatives, which may be developed as novel anticancer and immunostimulant agents.

TS-037671 — Novel non-peptidomimetic molecules for use as anti-cancer inhibitors of signal transducer and activator of transcription 3.

TS-037647 — A novel set of molecules that inhibit integrin-linked kinase in order to suppress tumor cell growth and metastasis.

TS-037569 — The constant activation of Signal Transducer and Activator of Transcription 3 (STAT3) is frequently detected in many cancer patients with advanced diseases. About 80% of all cancers overexpress STAT3, including solid tumors, lymphoma, and leukemia. Constant activation of STAT3 activities in nonmal…

TS-036754 — This technology aims to optimize the CRISPR-Cpf1 complex by chemically modifying the crRNA nucleotides and engineering crRNA sequences.

TS-032141 — The guide RNA is chemically modified to improve Cpf1 nuclease activity, reduce toxicity, decrease off-target effects, and increase stability.

TS-015117 — Analogues therapy to overcome multi-drug resistance in cancer cells

TS-015086 — Estrogen Receptor Beta Agonists for the treatment of breast, colon, and prostate cancers as well as inflammatory diseases.

TS-014842 — A new strategy for using androgen receptor ablative agents has been developed for prostate cancer therapy.

TS-014815 — An anti-tumor agent developed from indol-3-carbinol, a naturally occurring phytochemical in cruciferous vegetables.

TS-014754 — A novel anti-cancer agent (OSU-2S) that is devoid of S1P1 receptor activity and is highly effective in suppressing hepatocellular carcinoma tumor growth in vivo.

TS-014734 — A potential cancer treatment that suppresses the ability for cancer cells to intake glucose, thereby hampering cancer cell production.